Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 17.79B |
| Revenue (ttm) | 8.51B |
| Net Income (ttm) | 1.30B |
| Shares Out | n/a |
| EPS (ttm) | 8.90 |
| PE Ratio | 13.65 |
| Forward PE | 9.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 746 |
| Average Volume | 394 |
| Open | 123.25 |
| Previous Close | 123.05 |
| Day's Range | 121.35 - 123.35 |
| 52-Week Range | 99.00 - 181.65 |
| Beta | 0.11 |
| RSI | 54.35 |
| Earnings Date | Oct 31, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
A Look Into Biogen Inc's Price Over Earnings
Looking into the current session, Biogen Inc. (NASDAQ: BIIB) shares are trading at $145.60, after a 0.50% spike. Moreover, over the past month, the stock increased by 4.28% , but in the past year, fe...
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M
December 19th Options Now Available For Biogen (BIIB)
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the December 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...
Biogen (BIIB) to Acquire Alcyone Therapeutics for Innovative Drug Delivery System
Biogen (BIIB) to Acquire Alcyone Therapeutics for Innovative Drug Delivery System
Biogen to buy Massachusetts-based Alcyone Therapeutics
Biogen To Acquire Alcyone Therapeutics
(RTTNews) - Biogen Inc. (BIIB), a biotechnology company, on Thursday announced that it has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics for an upfront cash p...
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As pa...
Biogen (BIIB) Gains EU Approval for Post-Partum Depression Treatment
Biogen (BIIB) Gains EU Approval for Post-Partum Depression Treatment
Biogen (BIIB) Receives E.U. Approval for ZURZUVAE in Treating Postpartum Depression
Biogen (BIIB) Receives E.U. Approval for ZURZUVAE in Treating Postpartum Depression
Biogen gets EU nod for Zurzuvae to treat post-partum depression
Biogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum dep...
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat pos...
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News
Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector
Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector
Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...
Stocks making the biggest midday moves: Frontier Group, Kraft Heinz, Biogen and more
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest premarket moves: Kraft Heinz, PepsiCo, Biogen, Signet Jewelers and more
These are the stocks posting the largest moves in the premarket.
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...